

Prematurely ended - Statement

EudraCT Number: 2021-002818-13

Full title of the study: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5R α) in Adult Patients with Chronic Prurigo

Sponsor-Code: DEALSZ-2021-001

Short title: BICPIC

Sponsor: Charité – Universitätsmedizin Berlin; Institute of Allergology; Hindenburgdamm 30, 12203 Berlin

Contact name: Dr. Benjamin Grimmer
bicpic-ifa@charite.de

Product: Fasentra (Benralizumab)

Date of early termination: 2023/10/19

Statement: The trial was terminated early by the funder.